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Aim: With the rise in production of nanoparticles (NPs) for an ever-increasing number 
of applications, there is an urgent need to efficiently assess their potential toxicity. We 
propose a NP hazard assessment protocol that combines mammalian cytotoxicity data 
with embryonic vertebrate abnormality scoring to determine an overall toxicity index. 
Results: We observed that, after exposure to a range of NPs, Xenopus phenotypic 
scoring showed a strong correlation with cell based in vitro assays. Magnetite-cored 
NPs, negative for toxicity in vitro and Xenopus, were further confirmed as nontoxic in 
mice. Conclusion: The results highlight the potential of Xenopus embryo analysis as a 
fast screening approach for toxicity assessment of NPs, which could be introduced for 
the routine testing of nanomaterials.
First draft submitted: 1 October 2015; Accepted for publication: 21 December 2015; 
Published online: 22 March 2016
Keywords: cytotoxicity • in vitro–in vivo correlations • nanomaterials • nanomedicine  
• nanotoxicity • Xenopus laevis
Background
Objects at nanoscale (<100 nm) take on 
novel characteristics due to their small size 
and extensive surface area, providing mark-
edly different properties to develop reagents 
for biomedicine. As such, nanomaterials are 
being developed for an ever-increasing num-
ber of diseases including; infectious diseases, 
hepatitis, cardiac and vascular disorders, 
immune and degenerative diseases, and can-
cer [1]. However, their high surface area-to-
volume ratio renders nanoparticles (NPs) 
highly reactive, which can result in toxicity 
within biological systems [1–3]. At present a 
dedicated regulatory framework for testing 
nanomedicines does not yet exist and cell-
based assays are the current method of choice 
despite poor in vitro-in vivo correlations of 
nanomaterial toxicity [4]. Despite the increase 
in number of publications in nanomedicine 
over the past 5–10 years [5,6], it is often diffi-
cult to obtain conclusive results on the toxic-
ity of engineered nanomaterials, which is due 
to poor physico–chemical characterization of 
the material and a distinct lack of standard-
ized protocols [7]. This is seriously hampering 
the transfer of many promising nanomedi-
cines to the clinic.
Safety assessment is a necessary step in 
the process to develop a novel nanomedi-
cine and should involve further refinement at 
early stages in NP development to guarantee 
appropriate safety. Learning from the devel-
opment of first-generation nanomedicines 
that have been used in clinical procedures 
for years [8] and have been tested using the 
standard procedures for the evaluation of all 
drugs [9], it is desirable to develop methods 
that are tailored to evaluating specific toxici-
ties associated with nanomaterials. Recently, 
much effort from the nanocommunity has 
been directed to optimize protocols that 
assess the safety of nanomaterials. This con-
cept is known as ‘safety by design’ [5] and is 
crucial for the production of nanomedicines, 
for which engineering at the nanoscale can 
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Figure 1. Nanotoxicity screening assay workflow. A novel NP is characterized in assay buffers, cell (RPMI) and 
embryo (0.1 × MMR) culture media. Unstable or aggregating NPs can be redesigned or altered through surface 
modifications. Once a stable NP is fully characterized, an integrated protocol combining cytotoxicity screens in a 
range of cell types (cell viability and cell stress) and Xenopus laevis ranking of phenotype abnormalities is applied 
in parallel. The results are combined to produce a score that indicates if the NPs should be applied in a rodent 
model and further developed for pharmaceutical use.  
MMR: Marc’s modified ringers; NP: Nanoparticle.
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cause unpredictable biological responses [10]. A com-
promise has to be met in order to produce nanoma-
terials with desired properties (which for targeted 
treatments are often multifaceted, complex formula-
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tions), with tolerable toxicity and thus there is a need 
for robust screening methodologies at an early stage in 
NP development. Currently, the field requires a system 
that can bridge the safety assessment of NPs in cell-
based assays with reliable data generated from mam-
malian in vivo toxicity assessment, providing stronger 
correlations between the two toxicological models.
A preclinical screening tool that effectively assesses 
toxicity of nanomedicines prior to mammalian mod-
els will enormously reduce the number of materials 
that need to be tested in higher vertebrate systems, 
while also improving the success rates of novel nano-
materials to pass mammalian toxicity assessment 
models. Most new generation nanomedicines are 
multicomponent systems with complex chemical 
structures, joining the properties of different materi-
als in one unique engineered object, often involving 
the use of non-FDA approved materials. Therefore, 
there is a clear need to test the toxicity of the engi-
neered nano-object at different stages of production. 
Thus, one consequence of generating multicompo-
nent NPs for biomedical purposes is the potential of 
having to use a larger number of mammals for safety 
assessment than for the development of conventional 
drugs. It would be advantageous to test NP toxicity 
using a system that can bridge the gap in generat-
ing consistent data between in vitro cell-based assays 
and mammalian models of toxicity assessment [11,12]. 
Early developmental vertebrate models such as Danio 
rerio (zebrafish) and Xenopus laevis (African clawed 
frog) provide rapid and inexpensive systems for NP 
toxicity assessment, compared with adult mammalian 
models [11,13–15]. X. laevis produce embryos in sizeable 
quantities (adaptable for high-throughput screening) 
that are relatively large (∼1 mm in diameter at early 
stages of embryonic development), making them 
highly suitable in vivo systems for the assessment 
of toxicants. X. laevis has a long-running history in 
toxicity testing, such as the frog teratogenesis assay-
Xenopus (FETAX), which provides strong prediction 
of teratogens in mammals [16]. In addition they pro-
vide a means to investigate the toxicity of materials on 
whole organs, post organogenesis, to better simulate 
an adult model. Further advantages of using X. laevis 
as an in vivo toxicity model, include external develop-
ment of the embryo to allow for temporal control over 
the exposure to NPs and facilitating investigation 
into toxic effects at critical stages of embryogenesis, 
such as gastrulation and neuralation. Furthermore, 
X. laevis developmental stages are well characterized 
making it an ideal model for phenotypic assays [17,18]. 
The sensitivity of embryos during development can 
be exploited to identify varying degrees of toxicity 
by a range of phenotypic abnormalities, providing 
an indication into safe dosages; information that his-
torically is not accurately known before assessment in 
mammalian models.
In this study, we propose to use X. laevis embryos 
in combination with in vitro testing in mammalian 
cell lines to provide a multitiered, rapid and low cost 
approach to assess NP toxicity prior to in vivo mam-
malian testing. We have developed a methodology 
that assesses the toxicity of nanomaterials at an early 
stage in their production, before further assessment for 
translational applications (Figure 1). The methodology 
combines a full physicochemical characterization of 
the nanomaterial with quick and inexpensive in vitro 
cytotoxicity assays, and analysis in X. laevis embryos 
at different developmental stages, prior to mammalian 
testing.
Methods
NP synthesis & characterization
NH
2
-Fe
3
O
4
 and PS-COOH NPs were commercially 
available and therefore bought from Nanocs (prod-
uct code MP25-AM) and Invitrogen (product code 
F-8887), respectively. CdSe QDs and PEG-Fe
3
O
4
 NPs 
were synthesized in-house. All NPs were fully charac-
terized as described in the Supplementary Information. 
In addition, details about cell culture, all mouse pro-
cedures and statistical information is provided in the 
Supplementary Section.
Trypan blue exclusion assay
Cells were cultured as described in the 
Supplementary Information. A549 and SK-MEL-28 
lines were seeded at 26,550 cells/ml and MDCK 
at 20,000 cells/ml in 24 well-plates for trypan blue 
exclusion assay, which was carried out as previously 
described [19]. After attachment overnight, cells were 
exposed to different concentrations of NPs for 72 h 
before analysis.
MTT assay
Cell viability after exposure to NPs was assessed by 
MTT, as previously described [20]. Cells were seeded 
in 96-well plates at an initial density of 4500 cells/well 
and exposed to NPs for 72 h. Cell viability was calcu-
lated as a ratio of mean absorbance from quadruplicate 
readings, normalized to nonstimulated cells.
Immunoblotting
Cells were lysed in 50 mM Tris-HCl (pH 7.5), 1% Tri-
ton X-100, 150 mM NaCl and spun at 16,000 x g for 
30 min at 4°C. Immunoblotting was performed as pre-
viously described [21] using 1:1000 anti-PARP-1 (Santa 
Cruz Biotechnology) and 1:5000 anti-rabbit (Cell 
 Signaling) antibodies, in 5% BSA.
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X. laevis phenotypic assay
All experiments were performed in compliance with 
the relevant laws and institutional guidelines at the 
University of East Anglia. The research has been 
approved by the local ethical review committee accord-
ing to UK Home Office regulations. X. laevis embryos 
were obtained as previously described [22,23]. Embryos 
were staged using the Nieuwkoop and Faber (NF) nor-
mal table of Xenopus development [24]. Embryos devel-
oped at 18°C until they reached the required stage. 
Embryos (5 per well) were placed in a 24-well plate and 
exposed to NPs. Once at the required stage, embryos 
were washed twice with PBS before fixing in MEMFA 
(3.7% formaldehyde 1 × MEM salts, MQW [1:1:8]) 
overnight at 4°C. A further two PBS washes of the 
embryos was performed before embryos were scored 
for phenotypic abnormalities.
X. laevis whole mount florescence microscopy
NF stage 38 X. laevis embryos were exposed to 1015 NP/
ml PS-COOH until NF stage 45 and anaesthetized 
with 0.6 mg/ml ethyl 3-aminobenzoate methanesul-
fonate salt (Sigma Aldrich). PS-COOH NPs were 
imaged in the bloodstream of anaesthetized embryos 
using Nikon Eclipse 600 with a CCD digital camera, 
with an emission filter of 509–547 nm.
X. laevis transmission electron microscopy 
(TEM) imaging
Embryos exposed to 1015.3 NP/ml PEG-Fe
3
O
4
 during 
NF stage 38 to NF stage 45 were euthanized, fixed, 
embedded and sectioned as previously described [25]. 
Sections were observed using a Tecnai 20 TEM with 
AMT cameras, operating at an acceleration voltage of 
200 kV.
Results
NP synthesis & characterization
Our proposed nanotoxicity testing protocol (Figure 1) 
has been tested using four different NPs; CdSe quan-
tum dots (QD) NPs, pegylated magnetite NPs (Fe
3
O
4
-
PEG), amine-functionalized magnetite NPs (Fe
3
O
4
-
NH
2
) and fluorescent carboxylated polystyrene NPs 
(PS-COOH), selected for: a putative highly toxic NP 
as a positive control (QDs); two iron-oxide NPs (pos-
sible MRI contrast agents), with different surface func-
tionalization and physical chemical stability to test the 
ability of the protocol to detect potential differences 
in toxicity based on NP modifications [26,27]; and a 
negatively charged NP (PS-COOH) [28], being part of 
the first group of materials to be evaluated for safety 
at the nanoscale. Both QD and Fe
3
O
4
-PEG NPs were 
synthesized and purified in-house as explained in the 
material and methods section, while PS-COOH and 
Fe
3
O
4
-NH
2
 NPs were bought from specific suppliers 
and further characterized.
NP characterization is an essential first step in 
our protocol design (Figure 1). TEM and mean core 
sizes for the NPs are reported in Table 1, while statis-
tical analysis of the size together with representative 
images are shown in Supplementary Figure 1 in the 
Supplementary data section. NPs were also character-
ized by dynamic light scattering (DLS) and ζ-potential 
in aqueous dispersions (except for the Fe
3
O
4
-PEG 
NPs that were dispersed in PBS) which showed that 
hydrodynamic diameters were generally larger than 
TEM core sizes and that hydrodynamic sizes for QD 
and Fe
3
O
4
-NH
2
 NPs indicated the formation of NP 
clusters to some extent (Supplementary Figure 2A). 
NP stability and aggregation behaviors were studied 
in the embryo (0.1× Marc’s modified ringers [MMR]) 
and cell growth media (RPMI + 10% FBS) over 72 h, 
where the results at the starting time for the highest 
concentration measured are reported in Table 1. PS-
COOH and Fe
3
O
4
-PEG NPs were stable, while QD 
and Fe
3
O
4
-NH
2
 showed extensive aggregation at this 
concentration, however, aggregation was less extensive 
at lower concentrations for both NPs, demonstrating 
that further biological investigation was possible for all 
the NPs selected. NP hydrodynamic sizes in the differ-
Table 1. Structural parameters of the nanoparticles from transmission electron microscopy and 
dynamic light scattering measurements.
NP TEM (nm) Water/PBS Zeta potential 
(mV)
RMPI-1640 10% FBS 0.1 × MMR
  HDS (nm) PDI  HDS (nm) PDI HDS (nm) PDI
QD 4.5 ± 2.0 21.4 ± 1.5 0.1 -27.4 ± 0.0 107.5 ± 1.2 0.7 122 ± 1.5 0.1
PEG-Fe3O4 6.4 ± 1.2 21.9 ± 0.1 0.2 -3.9 ± 0.8 32.9 ± 3.0 0.2 22.1 ± 0.9 0.2
PS-COOH 22.6 ± 5.6 34.5 ± 0.7 0.2 -37.2 ± 2.0 75.4 ± 0.7 0.2 34.7 ± 0.7 0.2
NH2-Fe3O4 11.3 ± 2.9 90.0 ± 0.5 0.2 +30.3 ± 3.8 294.0 ± 2.3 0.4 2268 ± 96 0.2
FBS: Fetal bovine serum; HDS: Hydrodynamic diameter; MMR: Marc’s modified ringers; NP: Nanoparticle; PDI: Polydispersity index; 
QD: Quantum dot.
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ent environments were monitored over the experimen-
tal time for biological analysis and remained consistent 
as shown in Supplementary Figure 2B.
Cytotoxicity assessment analysis
We used a diverse array of mammalian cell types for 
cytotoxicity analysis (A549 [lung adenocarcinoma], 
SK-MEL-28 [melanoma] and MDCK [immortal-
ized kidney] cells; that represent commonly avail-
able lines), which were exposed to varying concen-
trations of NPs over 72 h. After NP stimulation, 
trypan blue exclusion assay, MTT assay and protein 
expression of full and cleaved poly (ADP-ribose) 
polymerase-1 (PARP-1) were performed to evaluate 
cytotoxic effects. Figure 2 shows the cytotoxic effects 
the NP panel in the three cell types, as a function of 
exposure concentration expressed as NP/ml (for clar-
ity analog graphs are reported vs concentration with 
different metrics [w/v and surface area/v] shown in 
Supplementary Figure 3, with representative images 
of the treated cells at the highest concentration of 
NP treatment shown in Supplementary Figure 4). As 
expected, QDs were highly toxic in all cell types for 
concentrations >1014 NP/ml, which corresponds to a 
weight concentration of 0.1 μg/ml. The MTT results 
showed that exposure to the highest concentrations 
of Fe
3
O
4
-NH
2
 and PS-COOH NPs on MDCK cells 
resulted in a 40% reduction in cell viability when 
compared with the other lines, while trypan blue 
results also showed reduced cell viability for the high-
est concentration of Fe
3
O
4
-NH
2
. PARP-1, activated 
by the production of reactive oxygen species (ROS), 
is a substrate for active cysteinyl-aspartate protease 
cleavage and is a marker of apoptotic cell death [29]. 
Previous studies have suggested an increase in ROS 
production after exposure to nanomaterials [30–32]. We 
investigated PARP-1 cleavage in the cells in response 
to NP treatment and found that only QDs induced 
apoptosis in cells at a comparable concentration to 
that of the cytotoxic drug, cisplatin, while no cleaved 
PARP-1 was observed in cells incubated with the other 
NPs (Figure 2C). Taken together these in vitro findings 
show that QDs induced high levels of cytotoxicity in 
mammalian cells compared with the other NPs tested.
Xenopus laevis as a multiparametric 
nanotoxicity assessment tool
Xenopus laevis embryos at different stages of devel-
opment were exposed to varying concentrations of 
NPs and morphological scoring of an array of phe-
notypic abnormalities was carried out (Figure 3A 
& Supplementary Figure 5). Phenotypic abnormalities 
were scored and used to assess the NP effect on the 
development of 30 embryos at all three of the selected 
stages. Common abnormalities recorded included; 
edema, blistering, eye deformities, loss of melano-
cytes, tail loss, stunted growth, axial defects such as 
bent spines, degradation of tissue and developmental 
delay (Figure 3A & B & Supplementary Figure 5). Based 
on these abnormalities embryos were scored collec-
tively as nonabnormal (healthy), abnormal or dead. By 
enabling all abnormalities to be marked in one cate-
gory, simplifies the scoring system and keeps subjectiv-
ity between users to a minimum. Gastrulation occurs 
at an early phase of vertebrate development (in Xenopus 
at NF stage 10) and is a highly sensitive time to envi-
ronmental changes during embryonic development, so 
to assess NP effects during this phase of development, 
embryos were exposed to the NPs at NF stage 4 and 
left to develop until NF stage 38 (Figure 3C). Another 
critical developmental process is neurulation, which 
occurs before organogenesis and gives rise to precursor 
tissues of the spinal cord, brain and neural crest [33]. To 
assess NP effects during neurulation and before organ-
ogenesis, embryos were exposed to the NPs at NF stage 
15 and left to develop until NF stage 38 (Figure 3D). 
Finally, for in vivo embryonic systems that can more 
accurately represent an adult system, embryos were 
exposed to NPs at tadpole stages during organogen-
esis, specifically at NF stage 38–45 (Figure 3B & E). 
QDs showed severe toxicity in X. laevis embryos at all 
stages, which is in good agreement with mammalian 
developmental systems [34], and our cytotoxicity data 
(Figure 2). The other NPs had limited toxicity, with the 
Fe
3
O
4
-NH
2
 and PS-COOH NPs showing toxic effects 
only at higher concentrations, while the Fe
3
O
4
-PEG 
NPs (synthesized in our laboratory as potential ther-
anostic NPs), showed no toxicity at all stages, which is 
also in accordance with our in vitro findings (Figure 2).
We wanted to check that NPs exhibiting low-to-
no toxicity in X. laevis embryos (iron oxide and PS-
COOH NPs) were taken up into the embryos following 
exposure. Embryo uptake by the iron oxide NPs and 
PS-COOH NPs was monitored by TEM imaging of 
embryo sections at NF stage 45 (Supplementary Figure 6) 
and fluorescence microscopy (FM) of live embryos 
at NF stage 45 (Supplementary Figure 7), respec-
tively. TEM analysis demonstrated the presence of 
the NPs in embryo tissues for both iron oxide NPs 
(Supplementary Figure 6). FM of intact embryos treated 
with PS-COOH NPs permitted us to detect their pres-
ence within the embryos, where NP uptake was pro-
portional to exposure (Supplementary Figure 7). More-
over, videos (Movie) of anesthetized embryos showed 
PS-COOH NPs (or agglomerates) moving through 
embryonic intersomatic blood vessels (from which 
time frame stills over 0.70 s have been extracted and 
are shown in Supplementary Figure 7B). Importantly, 
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Figure 2. Evaluation of nanoparticle cytotoxicity (please see facing page). (A & B) A549, SK-MEL-28 and MDCK cell 
lines were exposed to varying concentrations of QD, PEG-Fe3O4, PS-COOH and NH2-Fe3O4. After 72 h stimulation 
with NPs, trypan blue exclusion assay (A) and MTT assay (B) was performed to assess cell viability. Values represent 
mean ± SEM. MTT data also represented as alternative concentration indices (Supplementary Figure 3). (C) Protein 
expression of full length and cleaved PARP-1 in mammalian cell lines. Cells were stimulated for 24 h with 70 μM 
cisplatin (positive control), 1015.8 NP/ml QD, 1015.3 NP/ml PEG-Fe3O4, 10
15.9 NP/ml PS-COOH and 1015.5 NP/ml NH2-
Fe3O4. Control cells were vehicle treated. β-tubulin was used as a loading control. 
NP: Nanoparticle; QD: Quantum dot.
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these data show that the NPs used in this study are 
readily taken up by the X. laevis embryos.
Comparison of cytotoxicity & X. laevis data for 
hazard ranking of NPs
We developed a logical ranking system for correlating 
cytotoxicity and X. laevis results, to provide an overall 
hazard score from each assay for the investigated NPs 
(Tables 2 & 3). For the cytotoxicity data the hazard score 
was obtained for the highest NP concentration, while 
for the X. laevis analysis we only took into account the 
results generated from the tadpole stage (Figure 3E; NF 
38–45, when the embryo has fully formed organs and 
therefore the evaluation of nanotoxicity is more physi-
ologically relevant to adult tissues). The obtained haz-
ard indices are reported in Tables 2 & 3, which evaluates 
correlations between in vitro and in vivo results. The 
assays fully agreed on the evaluation of the toxicity for 
the highly toxic QDs that scored for severe toxic effects 
in all assays, as well as for the two iron oxide NPs that 
showed limited toxicity. However, PS-COOH NPs did 
not affect cell viability by the in vitro assays (Figure 2), 
yet exhibited toxicity effects at high concentrations as 
well as some moderate toxicity at lower concentrations 
in Xenopus (Figure 3). This suggests that the introduc-
tion of a X. laevis sampling test early on in NP develop-
ment could help to identify false negatives for toxicity 
assessment produced by cell-based assays.
Assessment of NP safety in a mammalian 
system
In our protocol (Figure 1) if NP-induced developmen-
tal defects are observed in the X. laevis model, the NP 
will not progress to further assessment, rather only 
those nanoformulations that give no-to-low toxicity 
will progress to evaluation in small rodent models (in 
our data this was the two iron oxide NPs; Figures 2 
& 3 & Tables 2 & 3). To validate the low-to-no toxic pre-
diction of the iron oxide NPs, we administered these 
two NPs in mice to assess toxicity effects on the tis-
sues where they accumulated (the target organs). For 
iron oxide core NPs, murine target organs could be 
easily identified using MRI analysis. MRI analysis 
showed that in T2-weighed MRI coronal slices from 
epigastric and mesogastric regions, both iron oxide 
NPs accumulated in the liver and kidneys of the NP-
treated animals compared with vehicle-treated controls 
(Figure 4A & B). Importantly, postmortem histological 
sections from the tissues where these NPs accumulated 
(the liver and kidneys) demonstrated not only that the 
iron distribution (as assessed by Perl’s staining) corrob-
orated the MRI findings, but importantly also failed 
to reveal any evidence of morphological tissue toxicity 
(Figure 4C) highlighting that these NPs exhibit little-
to-no toxicity in mammalian tissues. These findings 
show that X. laevis embryos are a useful tool to predict 
NP safety prior to administration and further testing 
in mammalian models.
Discussion & conclusion
With the growth of nanomedicines as therapies for dis-
ease management in the clinic, comes an ever increas-
ing need to effectively assess how nano-sized therapeu-
tics can effect biological systems and, in particular, 
systemic toxicity mechanisms [35]. As such, there has 
emerged a need for models that can produce effective 
toxicity data as a transition between 2D in vitro cell 
culture assays and expensive, often time-consuming 
in vivo mammalian models.
An alternative approach to mimic in vivo conditions 
has been to develop 3D and coculture in vitro cell-based 
models that better represent the organization of tissues 
compared with conventional 2D monocultures [36–41]. 
However, these tissue mimetic models are not without 
their limitations as they fail to recapitulate the com-
plete systemic interactions present between organ sys-
tems in vivo, but rather focus on the development of 
individual, tissue-specific models. An early vertebrate 
developmental model can provide a complete in vivo 
model system, but with the added advantage of being 
a rapid toxicity assessment tool. Specifically, we have 
proposed the use of X. laevis as a readily available labo-
ratory model to develop such a nanotoxicity screening 
tool (Figure 1). The protocol does not need to be lim-
ited to the exclusive use of Xenopus embryos, but rather 
can be easily extended to other commonly used devel-
opmental models such as the zebrafish model [11,42–44]. 
Amphibians share physiological traits common to all 
vertebrates, including mammals. Specific advantages 
of Xenopus as a model include; permeable skin, that 
they are tetrapods (therefore developing lungs and 
limbs), possessing all additional organs/tissues most 
commonly affected in human diseases (skin, sensory 
organs, lymphatic, nervous systems, kidneys, GI tract, 
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Figure 3. Xenopus laevis nanotoxicity phenotypic assay (for [A-D], please see facing page; for [E], please see above). (A) 
Representative images from the X. laevis phenotypic assay. (Ai) Control NF stage 38 embryo. (Aii) Control NF stage 45 embryo. 
(Aiii) embryo exposed to 1015.8 NP/ml QD at NF stage 38 and fixed at NF stage 45, all embryos were dead. (Aiv) Dorsal view of X. 
laevis with bent tail after exposure to 1014.2 NP/ml QD. (Av & Aviii)X. laevis exposed to 1015.8 NP/ml QD at NF stage 4 and fixed when 
control embryos reached NF stage 38. Abnormalities include eye deformities, stunted growth/development, edema, blistering and 
melanocyte deformities. (Avi & Avii) Embryo exposed to 1014.2 NP/ml QD. Abnormalities include stunted growth, bent spin and loss of 
pigmentation in the eye. (B) Representative images embryos exposed to 1015.8 NP/ml QD, 1015.6 NP/ml PEG-Fe3O4, 10
15.5 NP/ml PS-COOH 
and 1015.3 NP/ml NH2-Fe3O4. Embryos were developed in 0.1 × MMR and NP solution at different stages and fixed. The embryos were 
then analyzed for any developmental abnormalities or death. (C–E) Quantification of embryonic abnormalities. Histograms shown 
are of 30 embryos at each concentration of QD, PEG-Fe3O4, PS-COOH and NH2-Fe3O4. X. laevis assessed as healthy (no abnormalities), 
developmental defects (abnormalities) and death (dead) as indicated, at different concentrations of NPs. Developmental defects 
include eye malformations, bent spine/tail, edema, blistering and stunted growth, as shown in (A). (C) Embryos exposed at NF stage 
4 and fixed at NF stage 38, (D) embryos exposed at NF stage 15 and fixed at NF stage 38 and (E) embryos exposed at NF stage 38 and 
fixed at NF stage 45. 
NP: Nanoparticle; QD: Quantum dot.
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cardiovascular, hepatic and circulatory systems), they 
are the highest evolutionary order providing free-living 
embryos to permit screening in multiwell formats, and 
in earlier life stages prior to the onset of independent 
feeding (before NF 45), they are described under the 
EU directive as not protected as nonhuman verte-
brate models; thus making them highly amenable for 
toxicity testing procedures, as previously reviewed [18].
It is important that the physicochemical properties of 
the NPs are tested in the relevant biological fluids prior 
to toxicity assessment, so that the behavior of the NPs 
are well understood before proceeding to biological test-
ing, enabling us to infer whether or not toxicity profiles 
are in fact dependent on the nanomaterial itself or NP 
aggregation. For example, the high salt concentration in 
the X. laevis embryo MMR buffer, affected the stabil-
ity of electrostatically stabilized NPs such as QD and 
Fe
3
O
4
-NH
2
 (Table 1), while the presence of proteins with 
further formation of protein-NP complexes [45] reduces 
aggregation in such NPs, suggesting that once in vivo, 
following initial exposure to aggregating NPs, this 
aggregation will likely be reduced in biological fluids.
In this study, we selected four NPs that span a vari-
ety of materials and presented different toxicity indices 
to test the suitability of this as a nanotoxicity protocol. 
Fe
3
O
4
-NH
2
 NPs were found, according to our meth-
odology, as having low-to-no-toxicity and further tested 
in mice with no evidence of any major acute toxicity 
effect. We observed good agreement between in vitro 
and in vivo analysis for the nanomaterials tested, sug-
gesting that there is a good correlation between nano-
toxicity assessment in X. laevis and mammalian cells. 
The reputed toxic QD NPs and the iron oxide core NPs 
were ranked as toxic and low-to-no-toxicity, respec-
tively, which is in agreement with data reported by oth-
ers for similar NPs [46,47]. However, a significant con-
tradiction in the ranking of the PS-COOH NPs was 
found between in vitro and in vivo results. Specifically, 
cytotoxicity was not detected in the investigated con-
centration range by any of the cell-based assays used, 
while mortality and abnormalities were scored for the 
embryos at higher PS-COOH NP concentrations, thus 
highlighting the importance of a fully integrated cell 
line and X. laevis approach to accurately assess nanoma-
terial safety and to identify false negatives. The physical 
characterization of PS-COOH NPs in biological fluids 
did not show any agglomeration effects that could pro-
mote toxicity. However, there is experimental evidence 
in the literature of toxicity effects due to carboxylic sur-
face functionalization of polystyrene NPs is related to 
interaction with the blood plasma proteins [48,49]. FM 
on live embryos (Movie) confirmed the presence of high 
concentrations of PS-COOH NPs in the X. laevis tis-
sues. Therefore, a fundamental step in our protocol is 
the comparison between the in vitro cytotoxicity data 
and the in vivo findings in Xenopus (Figure 1).
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Moreover another toxicity aspect was tested, as the 
two chosen iron oxide NPs bearing specific surface 
functionalizations, showed different stability in the 
biological fluids at the highest concentration, where the 
Fe
3
O
4
-NH
2
 NPs aggregated extensively. This concentra-
tion-dependent agglomeration was more pronounced in 
the MMR buffer than in cell growth media, promoting 
mortality of the embryos at the highest Fe
3
O
4
-NH
2
 NP 
concentration, whereas no toxicity was observed for the 
lower concentrations at tadpole stages in the embryos 
(NF 38–45). This indicates that such a toxic effect was 
potentially related to the colloidal instability of the NPs 
rather than to the material composition of the NP itself. 
Instead, in vitro analysis provided mixed results depend-
ing on the cell line and of the assay that was used. Some 
toxicity was detected in the trypan blue exclusion assay 
at the highest concentration, which was not readily 
detectable in the MTT assay (Figure 2A & B). Of note, 
PARP-1 cleavage assay (Figure 2C) showed unambigu-
ously no apoptosis for all the treated cell lines at the 
highest NP concentration, highlighting that numerous 
cytotoxicity assays are required in combination to effec-
tively assess NP toxicity. Furthermore, cell line choice 
for nanotoxicity assessment provides a bespoke feature 
of this assay, where cell lines can be selected that are 
most suitable for analyzing nanomaterials designed for 
specific biomedical purposes.
For the X. laevis studies, we developed a simplified 
scoring system of the embryos allowing us to easily and 
rapidly assess NP-mediated toxicity in embryos at differ-
ing developmental stages (Figure 3C–E). We found that 
embryos exposed to PS-COOH NPs showed some toxic-
ity for all stages at higher concentrations, in particular at 
the earliest stage (NF 4–38), where toxicity was observed 
from concentrations >1014 NP/ml. Embryos exposed to 
Fe
3
O
4
-NH
2
 NPs showed toxicity at the earliest stage 
from concentrations >1014 NP/ml, while only at the high-
est NP concentration was 100% mortality observed at 
the other two stages of development. The severe toxicity 
observed at the highest concentration of Fe
3
O
4
-NH
2
 NPs 
was related to the extensive aggregation of these NPs in 
MMR medium, which resulted in precipitation at high 
concentrations. However, at the latest stage (NF 38–45), 
for which the embryo has developed most of its organs, 
no toxicity was observed at all the other concentrations 
for Fe
3
O
4
-NH
2
 NPs. Generally, we can state that where 
the embryos developed in the presence of NPs, NF stage 
4 to NF stage 38 showed more phenotypic abnormali-
ties and death at lower NP concentrations, than embryos 
exposed at NF stages 15 and 38. It is of note that between 
NF 38–45 the gills and mouth are open providing, in 
addition to the porous skin, possible respiratory and oral 
tract routes of exposure as well [50].
NPs were more toxic to embryos in early development 
(4–38 and 15–38 NF stages; Figure 3), in particular at 
the earliest stage, although it is difficult to say if this 
is connected to the different phase of development, or 
due to the longer exposure time to the NPs in these ani-
mals. While the first two stages might not be adaptable 
as prognostic model for toxicity in mammals, they can 
be used to evaluate teratogenesis. A study on X. laevis 
embryos, in which NPs were microinjected between 
NF stage 1 and 3, has shown that nanodiamond NPs 
with carboxylic surface groups promoted teratogenesis 
at both gastrulation and neurulation stages [51]. Other 
studies on X. laevis of metal oxide NPs (CuO, ZnO, etc.) 
have evaluated teratogenesis using the FETAX assay and 
reported major toxicity effects in the GI tract [14,25,52]. 
While FETAX focuses of teratogenic effects on mid-
blastula stage embryos, we have demonstrated X. laevis 
as a versatile model that can be used to predict toxicity 
of nanomaterials beyond teratogenic effects.
Our protocol predicts that the combined cytotoxic-
ity and X. laevis scores facilitate optimal prediction for 
toxicity in mammalian systems (Figure 1). Both iron 
core NPs gave a low hazard ranking for the cell culture 
Table 2. Hazard score obtained from the cell assays and embryo analysis.
Hazard Hazard score Cell viability (%) Healthy embryo (%)
0 0 >76 >76
x 1 50–75 50–75
xx 2 <50 <50
Table 3. Hazard score obtained from the cell assays and embryo analysis.
Nanoparticle MTT Trypan blue Xenopus laevis 
Quantum dot xx Xx xx
PEG-Fe3O4 0 0 0
PS-COOH 0 0 xx
NH2-Fe3O4 0 0 0
www.futuremedicine.com 653
Figure 4. Assessment of iron oxide nanoparticles in a mammalian model. (A) Representative MRI images showing coronal slices 
corresponding to the epigastric (left column) and mesogatric region (right column). (B) Histograms showing the gray levels in liver 
(upper panel) and kidney (lower panel) measured from vehicle- (black bars), Fe3O4-NH2 nanoparticles (NPs) (white bars) and Fe3O4-
PEG NPs treated mice (gray bars) at 1 or 5 days after NP administration. Data are expressed as mean ± SD. *p < 0.005; **p < 0.01, ***p 
< 0.0001 compared with the vehicle (Student’s t-test). (C) Perl’s stained tissue sections from target organs in treated animals. Tissues 
counter-stained with eosin. Representative images shown. Higher power images to highlight normal tissue structure in the NP treated 
animals are shown in Supplementary Figure 8. 
K: Kidneys; L: Liver.
Epigastric 
region
F
e 3
O
4-
P
E
G
12
0 
h
F
e 3
O
4-
P
E
G
12
0 
h
F
e 3
O
4-
N
H
2
12
0 
h
F
e 3
O
4-
N
H
2
24
 h
V
eh
ic
le
Mesogastric
region
F
e 3
O
4-
P
E
G
12
0 
h
F
e 3
O
4-
N
H
2
12
0 
h
V
eh
ic
le
Liver Kidneys
F
e
3O
4-
N
H
2
F
e
3O
4-
N
H
2
F
e
3O
4-
P
E
G
G
re
y 
va
lu
e
24 h 120 h
3
2
1
0
Kidneys
C
on
tr
ol
F
e
3O
4-
N
H
2
F
e
3O
4-
P
E
G
F
e
3O
4-
N
H
2
F
e
3O
4-
P
E
G
24 h 120 h
C
on
tr
ol
F
e
3O
4-
P
E
G
G
re
y 
va
lu
e
Liver
8
***
***
***
***
7
6
5
4
3
2
1
0
** *
future science group
Developmental model for nanomaterial safety    Research Article
and embryo assessment protocols (Tables 2 & 3). For this 
reason, we evaluated both these NPs in rodent models 
to confirm low toxicity. The other two NPs tested (PS-
COOH and QD NPs) caused toxicity in vivo and there-
fore in our protocol would not progress to rodent model 
testing (Figure 1). We intravenously injected Fe
3
O
4
 NPs 
into mice and monitored where they accumulated in the 
animals using MRI to identify those organs exposed to 
the NPs. Darkening of signal was used as an indication 
of the presence of iron oxide NPs in organs, identifying 
the parenchyma of the kidneys and liver as target tissues 
for these NPs. Quantification of gray values confirmed 
the MRI scanning and suggests a prolonged permanence 
of NPs in liver, but potential clearance in the kidneys. 
Histochemical staining of the liver and kidneys was con-
sistent with the MRI results, where crucially no histopa-
thologies were induced in these organs by prolonged NP 
exposure. Positive Perl’s staining was evident in liver of 
both Fe
3
O
4
-PEG and Fe
3
O
4
-NH
2
 treated animals, which 
was detected as a cytoplasmic granular blue staining of 
scattered interstitial cells. In renal tissue of both Fe
3
O
4
-
PEG and Fe
3
O
4
-NH
2
 treated animals staining within 
tubular epithelial cells was observed (Figure 4C). Neither 
presented with gross histopathological defects, demon-
strating there was no cytotoxic effects of the iron core 
NPs in these organs. Crucially these results validated our 
findings from the integrated cell line and X. laevis toxicity 
assessment protocol, showing that the iron oxide NPs did 
not induce major effects in mammalian models.
Conclusion
Overall, we have developed a powerful integrative 
tool for screening nanomaterials that can work as 
bridge between in vitro and in vivo analysis for nano-
toxicity. Our data demonstrate the flexibility of this 
multimodal preclinical assessment tool in the hazard 
assessment of nanomaterials, during the early stages of 
their production for biomedical applications. As such, 
functional modifications made to nanotherapeutics to 
enhance their efficacy, can be quickly analyzed using 
the protocol developed here for nanotoxic effects iden-
tified, which can then be addressed at an early stage in 
654 Nanomedicine (Lond.) (2016) 11(6) future science group
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development of the nanotherapy, prior to mammalian 
testing. This allows the rapid and cheap identifica-
tion of possible NP-induced toxicities that may not be 
detectable through conventional cytotoxicity assays, at 
an early stage in the  development of nanotherapeutics.
Future perspective
With the increase in development of nanotherapeutics 
and a lack of correlation between in vitro and in vivo 
safety assessment, there is now (more than ever) a need 
to develop standardized toxicity assessment protocols. 
We envisage that early developmental vertebrate mod-
els, such as Xenopus, can be easily integrated into a stan-
dardized safety protocol for novel nanomaterial testing, 
minimizing the time and cost of using mouse models 
and other higher vertebrates at an early stage in nano-
therapeutic design. Furthermore, information gathered 
from Xenopus will help to understand the behavior of 
new nanomedicines in whole organism systems.
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Executive summary
Xenopus laevis as a multiparametric nanotoxicity assessment tool
•	 We proposed X. laevis as a readily available laboratory model to develop a nanotoxicity screening tool and 
developed a simplified scoring system allowing us to easily and rapidly assess nanoparticle (NP) mediated 
toxicity in embryos at differing developmental stages.
Comparison of cytotoxicity & X. laevis data for hazard ranking of NPs
•	 The total scoring system combines cytotoxicity and X. laevis results for four different NPs for which a physical–
chemical characterization in the biological environment was also performed
Assessment of NP safety in a mammalian system
•	 NPs with a low hazard ranking for the cell culture and embryo assessment protocols did not show major 
histopathologies in the organs where they were accumulated in mice, indicating a good prediction of in vivo 
NP effects.
•	 We developed a fast and cheap tool for screening nanomaterials that can work as bridge between in vitro and 
in vivo analysis for early stage screening of nanotoxicity.
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